Nicotine Patch Therapy Based on Smoking Rate Followed by Bupropion for Prevention of Relapse to Smoking
To determine whether (1) tailored nicotine patch therapy that is based on smoking rate can be carried out in a multisite oncology investigative group practice setting, (2) long-term use of bupropion reduces the rate of relapse to smoking in smokers who stop smoking with nicotine patch therapy, and (...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2003-03, Vol.21 (5), p.914-920 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 920 |
|---|---|
| container_issue | 5 |
| container_start_page | 914 |
| container_title | Journal of clinical oncology |
| container_volume | 21 |
| creator | HURT, Richard D KROOK, James E MORTON, Roscoe F MICHALAK, John C SCHAEFER, Paul L PORTER, Patricia A STELLA, Philip J CROGHAN, Ivana T LOPRINZI, Charles L SLOAN, Jeff A NOVOTNY, Paul J KARDINAL, Carl G KNOST, James A TIRONA, Maria Tria ADDO, Ferdinand |
| description | To determine whether (1) tailored nicotine patch therapy that is based on smoking rate can be carried out in a multisite oncology investigative group practice setting, (2) long-term use of bupropion reduces the rate of relapse to smoking in smokers who stop smoking with nicotine patch therapy, and (3) bupropion can initiate smoking abstinence among smokers who have failed to stop smoking after nicotine patch therapy.
Fourteen North Central Cancer Treatment Group sites recruited generally healthy adult smokers from the general population for nicotine patch therapy and based the patch dosage on smoking rates. At completion of nicotine patch therapy, nonsmoking participants were eligible to be assigned to bupropion or placebo for 6 months (for relapse prevention). and smoking participants were eligible to be assigned to bupropion or placebo for 8 weeks of treatment.
Of 578 subjects, 31% were abstinent from smoking at the end of nicotine patch therapy. Of those subjects not smoking at the end of nicotine patch therapy who entered the relapse prevention phase, 28% and 25% were not smoking at 6 months (the end of the medication phase) for bupropion and placebo, respectively (P =.73). For those still smoking at the end of nicotine patch therapy, 3.1% and 0.0% stopped smoking with bupropion or placebo, respectively (P =.12).
Tailored nicotine patch therapy for the general population of smokers can be provided in a multisite oncology investigative group setting. Bupropion did not reduce relapse to smoking in smokers who stopped smoking with nicotine patch therapy. Bupropion did not initiate abstinence among smokers who failed to stop smoking with nicotine patch therapy. |
| doi_str_mv | 10.1200/JCO.2003.08.160 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73066351</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73066351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-ce96de223fe03e117fd5cb866fe51a3bf149e54e37694afa1949947bb4c16d493</originalsourceid><addsrcrecordid>eNpFkE1v1DAQhi1ERbctZ27IF7hl64k_Eh9hRSmoaqtSJG6W44x3U5I4tbNU_fd41a32NBrN874aPYR8ALaEkrHzn6ubZZ58yeolKPaGLECWVVFVUr4lC1bxsoCa_zkmJyk9MAai5vIdOYZSAQPNF2R93bkwdyPSWzu7Db3fYLTTM_1qE7Y0jPTXEP5245re2RnpRej78JQPTSa2UwxTlxEfIr2N-A_HebcGT--wt1NCOofX_Bk58rZP-H4_T8nvi2_3q8vi6ub7j9WXq8IJ0HPhUKsWy5J7ZBwBKt9K19RKeZRgeeNBaJQCeaW0sN6CFlqLqmmEA9UKzU_J55fe_NzjFtNshi457Hs7YtgmU3GmFJeQwfMX0MWQUkRvptgNNj4bYGbn1mS3ZufWsNpktznxcV-9bQZsD_xeZgY-7QGbnO19tKPr0oGTDJRicOA23Xrz1EU0abB9n2tL8-BCCUYaDYL_B9pdjnk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73066351</pqid></control><display><type>article</type><title>Nicotine Patch Therapy Based on Smoking Rate Followed by Bupropion for Prevention of Relapse to Smoking</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>HURT, Richard D ; KROOK, James E ; MORTON, Roscoe F ; MICHALAK, John C ; SCHAEFER, Paul L ; PORTER, Patricia A ; STELLA, Philip J ; CROGHAN, Ivana T ; LOPRINZI, Charles L ; SLOAN, Jeff A ; NOVOTNY, Paul J ; KARDINAL, Carl G ; KNOST, James A ; TIRONA, Maria Tria ; ADDO, Ferdinand</creator><creatorcontrib>HURT, Richard D ; KROOK, James E ; MORTON, Roscoe F ; MICHALAK, John C ; SCHAEFER, Paul L ; PORTER, Patricia A ; STELLA, Philip J ; CROGHAN, Ivana T ; LOPRINZI, Charles L ; SLOAN, Jeff A ; NOVOTNY, Paul J ; KARDINAL, Carl G ; KNOST, James A ; TIRONA, Maria Tria ; ADDO, Ferdinand</creatorcontrib><description>To determine whether (1) tailored nicotine patch therapy that is based on smoking rate can be carried out in a multisite oncology investigative group practice setting, (2) long-term use of bupropion reduces the rate of relapse to smoking in smokers who stop smoking with nicotine patch therapy, and (3) bupropion can initiate smoking abstinence among smokers who have failed to stop smoking after nicotine patch therapy.
Fourteen North Central Cancer Treatment Group sites recruited generally healthy adult smokers from the general population for nicotine patch therapy and based the patch dosage on smoking rates. At completion of nicotine patch therapy, nonsmoking participants were eligible to be assigned to bupropion or placebo for 6 months (for relapse prevention). and smoking participants were eligible to be assigned to bupropion or placebo for 8 weeks of treatment.
Of 578 subjects, 31% were abstinent from smoking at the end of nicotine patch therapy. Of those subjects not smoking at the end of nicotine patch therapy who entered the relapse prevention phase, 28% and 25% were not smoking at 6 months (the end of the medication phase) for bupropion and placebo, respectively (P =.73). For those still smoking at the end of nicotine patch therapy, 3.1% and 0.0% stopped smoking with bupropion or placebo, respectively (P =.12).
Tailored nicotine patch therapy for the general population of smokers can be provided in a multisite oncology investigative group setting. Bupropion did not reduce relapse to smoking in smokers who stopped smoking with nicotine patch therapy. Bupropion did not initiate abstinence among smokers who failed to stop smoking with nicotine patch therapy.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.2003.08.160</identifier><identifier>PMID: 12610193</identifier><language>eng</language><publisher>Baltimore, MD: American Society of Clinical Oncology</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Bupropion - therapeutic use ; Delayed-Action Preparations ; Dopamine Uptake Inhibitors - therapeutic use ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Humans ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; Nicotine - administration & dosage ; Pharmacology. Drug treatments ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Recurrence ; Smoking - epidemiology ; Smoking Cessation - methods ; Smoking Prevention ; Tobacco, tobacco smoking ; Toxicology ; Treatment Outcome</subject><ispartof>Journal of clinical oncology, 2003-03, Vol.21 (5), p.914-920</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-ce96de223fe03e117fd5cb866fe51a3bf149e54e37694afa1949947bb4c16d493</citedby><cites>FETCH-LOGICAL-c419t-ce96de223fe03e117fd5cb866fe51a3bf149e54e37694afa1949947bb4c16d493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27928,27929</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15016601$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12610193$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HURT, Richard D</creatorcontrib><creatorcontrib>KROOK, James E</creatorcontrib><creatorcontrib>MORTON, Roscoe F</creatorcontrib><creatorcontrib>MICHALAK, John C</creatorcontrib><creatorcontrib>SCHAEFER, Paul L</creatorcontrib><creatorcontrib>PORTER, Patricia A</creatorcontrib><creatorcontrib>STELLA, Philip J</creatorcontrib><creatorcontrib>CROGHAN, Ivana T</creatorcontrib><creatorcontrib>LOPRINZI, Charles L</creatorcontrib><creatorcontrib>SLOAN, Jeff A</creatorcontrib><creatorcontrib>NOVOTNY, Paul J</creatorcontrib><creatorcontrib>KARDINAL, Carl G</creatorcontrib><creatorcontrib>KNOST, James A</creatorcontrib><creatorcontrib>TIRONA, Maria Tria</creatorcontrib><creatorcontrib>ADDO, Ferdinand</creatorcontrib><title>Nicotine Patch Therapy Based on Smoking Rate Followed by Bupropion for Prevention of Relapse to Smoking</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>To determine whether (1) tailored nicotine patch therapy that is based on smoking rate can be carried out in a multisite oncology investigative group practice setting, (2) long-term use of bupropion reduces the rate of relapse to smoking in smokers who stop smoking with nicotine patch therapy, and (3) bupropion can initiate smoking abstinence among smokers who have failed to stop smoking after nicotine patch therapy.
Fourteen North Central Cancer Treatment Group sites recruited generally healthy adult smokers from the general population for nicotine patch therapy and based the patch dosage on smoking rates. At completion of nicotine patch therapy, nonsmoking participants were eligible to be assigned to bupropion or placebo for 6 months (for relapse prevention). and smoking participants were eligible to be assigned to bupropion or placebo for 8 weeks of treatment.
Of 578 subjects, 31% were abstinent from smoking at the end of nicotine patch therapy. Of those subjects not smoking at the end of nicotine patch therapy who entered the relapse prevention phase, 28% and 25% were not smoking at 6 months (the end of the medication phase) for bupropion and placebo, respectively (P =.73). For those still smoking at the end of nicotine patch therapy, 3.1% and 0.0% stopped smoking with bupropion or placebo, respectively (P =.12).
Tailored nicotine patch therapy for the general population of smokers can be provided in a multisite oncology investigative group setting. Bupropion did not reduce relapse to smoking in smokers who stopped smoking with nicotine patch therapy. Bupropion did not initiate abstinence among smokers who failed to stop smoking with nicotine patch therapy.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Bupropion - therapeutic use</subject><subject>Delayed-Action Preparations</subject><subject>Dopamine Uptake Inhibitors - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Nicotine - administration & dosage</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Recurrence</subject><subject>Smoking - epidemiology</subject><subject>Smoking Cessation - methods</subject><subject>Smoking Prevention</subject><subject>Tobacco, tobacco smoking</subject><subject>Toxicology</subject><subject>Treatment Outcome</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1v1DAQhi1ERbctZ27IF7hl64k_Eh9hRSmoaqtSJG6W44x3U5I4tbNU_fd41a32NBrN874aPYR8ALaEkrHzn6ubZZ58yeolKPaGLECWVVFVUr4lC1bxsoCa_zkmJyk9MAai5vIdOYZSAQPNF2R93bkwdyPSWzu7Db3fYLTTM_1qE7Y0jPTXEP5245re2RnpRej78JQPTSa2UwxTlxEfIr2N-A_HebcGT--wt1NCOofX_Bk58rZP-H4_T8nvi2_3q8vi6ub7j9WXq8IJ0HPhUKsWy5J7ZBwBKt9K19RKeZRgeeNBaJQCeaW0sN6CFlqLqmmEA9UKzU_J55fe_NzjFtNshi457Hs7YtgmU3GmFJeQwfMX0MWQUkRvptgNNj4bYGbn1mS3ZufWsNpktznxcV-9bQZsD_xeZgY-7QGbnO19tKPr0oGTDJRicOA23Xrz1EU0abB9n2tL8-BCCUYaDYL_B9pdjnk</recordid><startdate>20030301</startdate><enddate>20030301</enddate><creator>HURT, Richard D</creator><creator>KROOK, James E</creator><creator>MORTON, Roscoe F</creator><creator>MICHALAK, John C</creator><creator>SCHAEFER, Paul L</creator><creator>PORTER, Patricia A</creator><creator>STELLA, Philip J</creator><creator>CROGHAN, Ivana T</creator><creator>LOPRINZI, Charles L</creator><creator>SLOAN, Jeff A</creator><creator>NOVOTNY, Paul J</creator><creator>KARDINAL, Carl G</creator><creator>KNOST, James A</creator><creator>TIRONA, Maria Tria</creator><creator>ADDO, Ferdinand</creator><general>American Society of Clinical Oncology</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030301</creationdate><title>Nicotine Patch Therapy Based on Smoking Rate Followed by Bupropion for Prevention of Relapse to Smoking</title><author>HURT, Richard D ; KROOK, James E ; MORTON, Roscoe F ; MICHALAK, John C ; SCHAEFER, Paul L ; PORTER, Patricia A ; STELLA, Philip J ; CROGHAN, Ivana T ; LOPRINZI, Charles L ; SLOAN, Jeff A ; NOVOTNY, Paul J ; KARDINAL, Carl G ; KNOST, James A ; TIRONA, Maria Tria ; ADDO, Ferdinand</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-ce96de223fe03e117fd5cb866fe51a3bf149e54e37694afa1949947bb4c16d493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Bupropion - therapeutic use</topic><topic>Delayed-Action Preparations</topic><topic>Dopamine Uptake Inhibitors - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Nicotine - administration & dosage</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Recurrence</topic><topic>Smoking - epidemiology</topic><topic>Smoking Cessation - methods</topic><topic>Smoking Prevention</topic><topic>Tobacco, tobacco smoking</topic><topic>Toxicology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HURT, Richard D</creatorcontrib><creatorcontrib>KROOK, James E</creatorcontrib><creatorcontrib>MORTON, Roscoe F</creatorcontrib><creatorcontrib>MICHALAK, John C</creatorcontrib><creatorcontrib>SCHAEFER, Paul L</creatorcontrib><creatorcontrib>PORTER, Patricia A</creatorcontrib><creatorcontrib>STELLA, Philip J</creatorcontrib><creatorcontrib>CROGHAN, Ivana T</creatorcontrib><creatorcontrib>LOPRINZI, Charles L</creatorcontrib><creatorcontrib>SLOAN, Jeff A</creatorcontrib><creatorcontrib>NOVOTNY, Paul J</creatorcontrib><creatorcontrib>KARDINAL, Carl G</creatorcontrib><creatorcontrib>KNOST, James A</creatorcontrib><creatorcontrib>TIRONA, Maria Tria</creatorcontrib><creatorcontrib>ADDO, Ferdinand</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HURT, Richard D</au><au>KROOK, James E</au><au>MORTON, Roscoe F</au><au>MICHALAK, John C</au><au>SCHAEFER, Paul L</au><au>PORTER, Patricia A</au><au>STELLA, Philip J</au><au>CROGHAN, Ivana T</au><au>LOPRINZI, Charles L</au><au>SLOAN, Jeff A</au><au>NOVOTNY, Paul J</au><au>KARDINAL, Carl G</au><au>KNOST, James A</au><au>TIRONA, Maria Tria</au><au>ADDO, Ferdinand</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nicotine Patch Therapy Based on Smoking Rate Followed by Bupropion for Prevention of Relapse to Smoking</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2003-03-01</date><risdate>2003</risdate><volume>21</volume><issue>5</issue><spage>914</spage><epage>920</epage><pages>914-920</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>To determine whether (1) tailored nicotine patch therapy that is based on smoking rate can be carried out in a multisite oncology investigative group practice setting, (2) long-term use of bupropion reduces the rate of relapse to smoking in smokers who stop smoking with nicotine patch therapy, and (3) bupropion can initiate smoking abstinence among smokers who have failed to stop smoking after nicotine patch therapy.
Fourteen North Central Cancer Treatment Group sites recruited generally healthy adult smokers from the general population for nicotine patch therapy and based the patch dosage on smoking rates. At completion of nicotine patch therapy, nonsmoking participants were eligible to be assigned to bupropion or placebo for 6 months (for relapse prevention). and smoking participants were eligible to be assigned to bupropion or placebo for 8 weeks of treatment.
Of 578 subjects, 31% were abstinent from smoking at the end of nicotine patch therapy. Of those subjects not smoking at the end of nicotine patch therapy who entered the relapse prevention phase, 28% and 25% were not smoking at 6 months (the end of the medication phase) for bupropion and placebo, respectively (P =.73). For those still smoking at the end of nicotine patch therapy, 3.1% and 0.0% stopped smoking with bupropion or placebo, respectively (P =.12).
Tailored nicotine patch therapy for the general population of smokers can be provided in a multisite oncology investigative group setting. Bupropion did not reduce relapse to smoking in smokers who stopped smoking with nicotine patch therapy. Bupropion did not initiate abstinence among smokers who failed to stop smoking with nicotine patch therapy.</abstract><cop>Baltimore, MD</cop><pub>American Society of Clinical Oncology</pub><pmid>12610193</pmid><doi>10.1200/JCO.2003.08.160</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2003-03, Vol.21 (5), p.914-920 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73066351 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Bupropion - therapeutic use Delayed-Action Preparations Dopamine Uptake Inhibitors - therapeutic use Drug Therapy, Combination Female Follow-Up Studies Humans Male Medical sciences Middle Aged Neuropharmacology Nicotine - administration & dosage Pharmacology. Drug treatments Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Recurrence Smoking - epidemiology Smoking Cessation - methods Smoking Prevention Tobacco, tobacco smoking Toxicology Treatment Outcome |
| title | Nicotine Patch Therapy Based on Smoking Rate Followed by Bupropion for Prevention of Relapse to Smoking |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T13%3A54%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nicotine%20Patch%20Therapy%20Based%20on%20Smoking%20Rate%20Followed%20by%20Bupropion%20for%20Prevention%20of%20Relapse%20to%20Smoking&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=HURT,%20Richard%20D&rft.date=2003-03-01&rft.volume=21&rft.issue=5&rft.spage=914&rft.epage=920&rft.pages=914-920&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.2003.08.160&rft_dat=%3Cproquest_cross%3E73066351%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73066351&rft_id=info:pmid/12610193&rfr_iscdi=true |